TL;DR
This study links resistance-associated cellular states to a functionally validated regulator and provides an integrative framework for identifying clinically relevant regulators of chemotherapy resistance in bladder cancer.
Chemotherapy resistance remains a formidable challenge in cancer treatment, driving high mortality rates worldwide. Despite significant advancements, it remains unclear whether conserved molecular programs underpin therapy resistance across cancer types. Here, we integrate single-cell RNA sequencing, spatial transcript...
Platinum resistance remains a central barrier to durable disease control in ovarian cancer. In this study, we integrated an ovarian cancer susceptibility GWAS, multi-omics profiling (CPTAC/TCGA), and spatial-single-cell transcriptomics to identify novel therapeutic targets. Cross-platform prioritization nominated m...
The present findings identified CCT2 as a key mediator of cisplatin resistance in LUAD and provided potential therapeutic strategies to overcome chemotherapy resistance.
These findings identify CDC20 as a recurrence-associated molecular node involved in BaP-responsive malignant biological phenotypes and provide a phenotype-anchored framework linking recurrence biology with environmental exposure-related tumor behavior.
Small cell lung cancer (SCLC) represents the most lethal subtype of lung carcinoma. Platinum-based agents, such as cisplatin and carboplatin, remain the cornerstone of first-line therapy for patients with SCLC, whether administered as chemotherapy alone or in combination with immunotherapy. However, patients frequently...
This study characterizes a specific DHCR24+ tumor epithelial subpopulation that orchestrates cisplatin resistance via the "cholesterol-lipid raft-MAPK" axis and establishes a clear mechanistic link between cholesterol metabolism and cisplatin sensitivity.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
